- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01749280
Magnetic Resonance Imaging To Predict Outcomes In Aortic Aneurysms
11. desember 2012 oppdatert av: University of Edinburgh
Efficacy of Magnetic Resonance Imaging Using Ultrasmall Superparamagnetic Particles of Iron Oxide to Predict Clinical Outcome in Patients Under Surveillance for Abdominal Aortic Aneurysms
The aorta is the main blood vessel that comes out of the heart and distributes blood to the whole body.
In some people, the aorta becomes swollen (aneurysm) and bursts, especially as it passes through the abdomen.
These 'abdominal aortic aneurysms' often occur without symptoms and can burst or rupture without warning.
This usually leads to death and represents the thirteenth commonest cause of death in the United Kingdom.
In this study, we are looking at a new technique that can look at the aortic aneurysm using magnetic resonance imaging; a technique that does not require x-rays or radiation.
We have recently shown that, using magnetic resonance combined with a new imaging agent USPIO, we can detect 'hotspots' of activity in these aneurysms that seem to predict which aneurysms grow rapidly, and are therefore potentially at risk of rupture.
We here propose to conduct a study in Edinburgh that will invite all patients who are under surveillance because of an aneurysm.
We will image these patients using this novel technique and see if we can identify which patients burst their aneurysm, have an aneurysm that grows so large it needs to have surgery, or die.
This will be important to establish as it will potentially lead to a new way of managing people that could ultimately save lives.
This is particularly timely as national screening and surveillance programmes are currently being launched.
Studieoversikt
Status
Avsluttet
Forhold
Detaljert beskrivelse
HYPOTHESIS We hypothesise that uptake of ultrasmall supraparamagnetic particles of iron oxide into the aortic wall will predict abdominal aortic aneurysm growth and clinical outcomes.
Studietype
Observasjonsmessig
Registrering (Faktiske)
16
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
-
Edinburgh, Storbritannia, EH16 4SB
- Clinical Research Imaging Centre/ NHS LOTHIAN
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
40 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Prøvetakingsmetode
Ikke-sannsynlighetsprøve
Studiepopulasjon
The investigators will recruit 237 patients with abdominal aortic aneurysms from the clinical surveillance programme at the Royal Infirmary, Edinburgh.
Inclusion criteria will be patients with an abdominal aortic aneurysm >40 mm on ultrasound scanning.
Exclusion criteria will include patients with anticipated or planned abdominal aortic aneurysm repair, women of child-bearing potential without contraception, inability to undergo magnetic resonance or computed tomography scanning, life expectancy of <2 years, and those with any form of collagen-vascular disease.
Beskrivelse
Inclusion Criteria:
Patients with an abdominal aortic aneurysm >40 mm
Exclusion Criteria:
- Any medical history or clinically relevant abnormality identified on the screening medical examination, vital sign measurement, or clinical laboratory examination that is deemed by the principal investigator and/or designee to make the subject ineligible for inclusion.
- Subjects with planned AAA surgery.
- Renal impairment with eGFR of <30 mls/min at screening, history of kidney transplant or history of contrast nephropathy.
- Women of child-bearing potential without contraception,
- Collagen-vascular disease.
- Inability to undergo magnetic resonance or computed tomography scanning,
Contraindication to MRI scanning (as assessed by local MRI safety questionnaire) which includes but not limited to:
- Intracranial aneurysm clips (except Sugita) or other metallic objects,
- History of intra- orbital metal fragments that have not been removed,
- Pacemakers, implantable cardiac defibrillators and non-MR compatible heart valves,
- Inner ear implants,
- History of claustrophobia in MR.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
|---|
|
Abdominal Aortic Aneurysms
Patients will be recruited from the outpatient AAA surveillance population at the vascular unit in the Royal Infirmary of Edinburgh.Potential participation in the study will be completely asymptomatic from their AAA.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
To determine if uptake ultrasmall superparamagnetic particles of iron oxide as determined by percentage R2* change between pre-and post-constant scan will predict abdominal aortic aneurysm growth and rupture in patients with abdominal aortic aneurysms.
Tidsramme: 2 yrs
|
The change of R2* signal which is determined by the USPIO uptake within the issues will be used to assess the change between pre-and post contrast MRI scans.
The investigators will assess if macrophage activity as determined by USPIO change predicts AAA growth and rupture
|
2 yrs
|
|
Does USPIO uptake as determined by percentage change between pre-and post contrast scan co-relates with FDG PET standardised uptake values or tissue to background ratios.
Tidsramme: 2 yrs
|
As per ethical approval, we have recruited patients under AAA PET study to look at USPIO correlation with 18F-FDG PET.
The cellular inflammation can be assessed by USPIO uptake, whilst the metabolic activity can be determined by 18F-FDG PET.
In this study, the investigators will determine if there is a correlation between the these two imaging modalties by comparing the R2* change using MRI and standardised uptake values using FDG PET.
|
2 yrs
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: David Newby, MD PhD, University of Edinburgh
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. mars 2011
Primær fullføring (Faktiske)
1. august 2012
Studiet fullført (Faktiske)
1. august 2012
Datoer for studieregistrering
Først innsendt
30. november 2012
Først innsendt som oppfylte QC-kriteriene
11. desember 2012
Først lagt ut (Anslag)
13. desember 2012
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
13. desember 2012
Siste oppdatering sendt inn som oppfylte QC-kriteriene
11. desember 2012
Sist bekreftet
1. desember 2012
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 2011/R1CARl05
- 10336 (Registeridentifikator: UKRCN)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .